No 02 2023

The company has received regulatory approval from the European Medicines Agency, to conduct PP-CT04, a two-part, randomized, double-blind, placebo-controlled, parallel-group, 12‑week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants.

BioArctic and Mesenkia Therapeutics have signed a research collaboration agreement to explore a novel antibody-based approach for glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, where effective delivery of large molecules to the brain remains a major challenge.

The Lundbeck Foundation has awarded DKK 78 million to a pan-Nordic centre that will focus on research into the glymphatic system.

Navinci Diagnostics has initiated a collaboration with BrainZell to explore the use of Navinci’s in situ Proximity Ligation Assay technology in human brain organoid models to support relevant studies of biology and drug response.

The Board of Directors of BICO Group AB has announced the appointment of Anders Fogelberg, currently Chief Commercial Officer, as President and CEO, effective September 1, 2026.

Hansa Biopharma has announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).

LEO Pharma is acquiring worldwide rights to dersimelagon from Japan’s Tanabe Pharma in a deal worth up to USD 435 million, strengthening the Danish company’s rare dermatology pipeline.